Effects of L-ascorbate 2-sulfate (AAS) on fatty liver and hyperlipidemia induced by various treatments were studied in rats and guinea pigs. L-Ascorbic acid (AA) (50 or 175mg/kg), a reference compound, lowered the lipid levels in the serum and/or liver in guinea pigs, while AA had little effect in rats. On the other hand, AAS (300 mg/kg) was effective in both animals . In rats, AAS lowered cholesterol and triglycerides in the serum from ethionine-treated animals and in the liver from orotic acid-supplemented animals . In guinea pigs, this compound lowered cholesterol and triglycerides in the serum from ethionine-treated animals, lipids in the liver from cholesterol supplemented animals, and lipids in the serum and liver from scorbutic animals. AA markedly increased the content of AA in the organs in all experiments, while AAS had a slight effect . Thus, it is suggested that AAS exerts its hypolipidemic and lipotropic effects by the specific actions of AAS.
(Fuji Mill Co., Shizuoka) which is unsupplemented with AA and contains 9.0mg of AA per 100g diet, with 0.5% cholesterol for 4 weeks. Non-treated group received diet IV without cholesterol supplement. Animals were kept pair-fed with diets of 30g per a day. In Exp. 6, scorbutic groups received diet I which contains 2.0mg of AA per 100g and non-scorbutic control received diet IV. All animals received 1mg of AA in 20% sucrose solution (1mg/ml) orally once a day during the first 2 weeks. Animals were kept pair-fed (20 to 25g/animal/day). Experimental period was 4 weeks.
In Exp. 7, all groups received diet I, and the treated groups were given 50mg of ethionine per kg daily orally. DL-Ethionine was dissolved in 20% sucrose solution (20mg/ml). Animals were kept pair-fed (10 to 15g/animal/day). Experi mental period was 1 week.
AAS (100 or 300mg/kg) or AA (50 or 175mg/kg) was administered orally once a day. The drugs were dissolved in a 20% sucrose solution, and 1 ml of the solution was given per 500g body weight. The control groups with or without treatment were given the vehicle only.
The dose of AA was selected as an approximate molar equivalent to 300 mg/kg of AAS (175mg/kg) or as an approximate concentration usually supplemented in a diet for guinea pigs (50mg/kg).
Determination of lipids and AA. Determinations of lipids in serum and liver and AA in various organs were carried out as described in previous papers (4, 6) . The results were statistically analyzed using Student's t-test.
RESULTS

Experiments in rats with various treatments
Exp. 1 with ethionine treatment. By ethionine treatment, the growth rate was decreased but the relative liver weight (g/100g body weight) was increased by 20.3%. AAS and AA did not affect these parameters (Table 1) .
With ethionine treatment, the serum level of triglycerides was increased by 172.5% and the contents of cholesterol and triglycerides in liver (mg/g) were increased by 12.0 and 42.3%, respectively. Administration of AAS and AA had little effect on liver lipid levels, while these compounds tended to decrease the serum lipid levels. The serum cholesterol level was significantly lowered by AAS (45.2%) ( Table 2) .
The contents of AA in liver and spleen were lowered by 51.9 and 16.4%, respectively, in the ethionine-treated control. The AA content in liver and spleen was increased by AA administration, but not by AAS (Table 3) .
Exp. 2 with orotic acid supplement. The growth rate was not changed, while the relative liver weight was increased by 48.100 by orotic acid supplement. The increment of liver weight was completely prevented by administration of adenine, but not by AAS (Table 1) .
By treatment with orotic acid, the serum lipid levels were little influenced, but the contents of cholesterol and triglycerides in liver were increased 1,8-and 8.8-fold, respectively. AAS decreased cholesterol and triglycerides in liver by 17 .5 and 3O.6%, respectively. With administration of adenine, the lipids in liver were more markedly decreased (cholesterol, 77.2%; triglycerides, 97.7%), but the serum level of triglycerides was significantly increased (54.5%) ( Table 2 ).
The content of AA was decreased in liver by 29.3%, and increased in spleen and kidney by 39.0 and 56.6%, respectively, in the orotic acid-treated control, but the increased AA in spleen and kidney was decreased significantly by adminis tration of AAS by 17.9 and 17.6%, respectively, and by the adenine by 31.1 and 25.0%, respectively (Table 3) .
Exp. 3 with cholesterol supplement. The growth rate was slightly increased and the relative liver weight was increased significantly (14.0%) by cholesterol feeding. Administration of AAS and AA did not alter these parameters (Table 1) .
By cholesterol feeding, serum levels of cholesterol and triglycerides were increased 4.9-and 1.3-fold, respectively, and the cholesterol and triglycerides in liver were increased 6.4-and 5.3-fold, respectively. The serum and liver lipid levels were not affected by administration of AAS and AA (Table 2) .
There was no difference in the content of AA between control groups with or without cholesterol supplement. Administration of AA resulted in a significant increase of the AA content in liver (80.9%), spleen (43.9%), kidney (65.8%) and adrenal gland (22.4%), while administration of AAS did not alter the content (Table 3) .
Experiments in guinea pigs with various treatments
Exp. 4 with ethionine treatment. The growth rate was decreased and the relative liver weight was increased (69.4%) by ethionine treatment. These parameters were little changed by administration of AAS and AA (Table 4) .
With ethionine treatment, serum levels of cholesterol and triglycerides were increased 1.6-and 10.2-fold, respectively, and the contents of cholesterol and triglycerides in liver were raised 1.5-and 15.9-fold, respectively. Administration of AAS and AA markedly decreased the serum lipid levels (cholesterol:40.0 and 30.0%, respectively; triglycerides; 71.6 and 68.3%, respectively), while these compounds had little affect on the liver lipid levels ( Table 5 ).
The content of AA was increased by 47.7% in liver but decreased by 26.6% in adrenal in ethionine-treated control. The content of AA in organs was increased markedly by administration of AA (83.7 to 203.8%) and slightly by administration of AAS (14.8 to 48.4%) ( Table 6) .
Exp. 5 with cholesterol supplement. The growth rate was little influenced, but the relative liver weight was increased significantly (35.0%) by cholesterol feeding. AAS and AA did not change these parameters (Table 4) .
With cholesterol supplement, the cholesterol level in serum and liver, and the triglyceride level were increased 5.2-, 5.4-and 7.9-fold, respectively. Administration of AAS resulted in a decrease of the contents of cholesterol (34 .3% without significance) and triglyceride (35.0% with significance) in liver. Administration of AA tended to decrease the liver lipid levels ( Table 5 ) . The content of AA was decreased in liver, spleen and adrenal by 16 .8, 47.8 and 36.0%, respectively, in cholesterol-fed control. The content in these organs was increased markedly by administration of AA (117 .9 to 176.3%) and slightly by AAS (Table 6 ).
Exp. 6 with scorbutigenic diet. The growth rate was slightly decreased in scorbutic control, but not in animals administered AAS (300mg/kg) and AA (50 mg/kg). The relative liver weight was increased by 21 .7% in the scorbutic control. AAS and AA did not affect this parameter (Table 4) .
Compared to the non-treated control, the serum levels of cholesterol and triglycerides were increased by 82 .5% (with significance) and 73.2% (without significance), respectively, in the scorbutic control . The cholesterol level in serum and liver was decreased by AAS at the doses of 300 mg/kg (50 .3 and 16.7%, respectively), but not decreased by the compound at the dose of 100mg/kg . Administration of AA also significantly decreased the serum cholesterol by 27 .8%. Both AAS and AA tended to decrease the triglyceride level in serum and liver (Table 5) .
The content of AA in organs was decreased markedly in the scorbutic control (approx. 90% in all organs). The content was increased markedly by administration of AA (6.1-to 11.6-fold), but slightly by AAS (less than 2 .4-fold) ( Table 6 ). Exp. 8 with ethionine treatment in scorbutic animals. The growth rate was little influenced, while the relative liver weight was increased by 25 .8% by treatment with ethionine. AAS and AA did not affect these parameters (Table 4) .
By the one-week treatment with ethionine, the contents of cholesterol and triglycerides in liver were significantly increased by 13 .2 and 102.5%, respectively. The serum lipid levels tended to increase . AAS tended to decrease the serum lipid levels ( Table 5 ).
The content of AA was increased in liver (33 .6%) and spleen (41.7%) by ethionine treatment. The content in organs was increased significantly by administration of AA (47.8 to 126.3%), but not by AAS (Table 6 ) .
DISCUSSION
The effects of AAS on fatty liver and hyperlipidemia induced by various nutritional disturbances were studied in rats and guinea pigs .
Remarkable decrease in the growth rate was observed only in the experiment treated with ethionine, while a significant increase in the relative liver weight was shown in all experiments (Tables 1 and 4) .
Lipid levels in the serum and liver were increased by these treatments as follows. In rats, the triglycerides were mainly increased by ethionine and orotic acid treatments, and both cholesterol and triglycerides by cholesterol-feeding . In guinea pigs, triglycerides were increased by ethionine treatment in normal and scorbutic animals, and cholesterol by a scorbutigenic diet, and both cholesterol and triglycerides by cholesterol-feeding (Tables 2 and 5 ). These changes in lipid levels in animals with various treatments were coincident with the results reported by others (9-13), except for experiments with ethionine. There have been many reports indicating that an acute administration of ethionine in higher concentrations such as 1,000 or 3,000mg/kg resulted in an increase of triglycerides in the liver and a decrease in the serum (13, 14) . It was suggested that ethionine inhibits the release of lipoprotein from liver, thus resulting in an accumulation of triglycerides in the liver and a decrease in the serum. In our experiments in rats and guinea pigs, in which ethionine was administered in smaller doses (50 to 400mg/kg) for 1 to 2 weeks, there were, however, increases in the serum triglycerides as well as an accumulation of triglycerides in the liver.
Changes of the content of AA in organs were observed as well, since AAS is a derivative of AA. In rats, the AA content in liver was decreased in ethionine-and orotic acid-treated control, but not changed in cholesterol-fed control. In guinea pigs, the AA content was increased in ethionine-treated control, but decreased in scorbutic and cholesterol-fed controls (Tables 3 and 6 ).
Kato (15) has reported that an administration of ethionine to rats markedly decreased the AA content in the liver and increased the urinary excretion of AA, and suggested that ethionine may decrease the storage of AA in liver.
Regarding the effects of ethionine, there were remarkable differences between rats and guinea pigs. Guinea pigs were more sensitive to ethionine compared to rats in inducing fatty liver and hyperlipidemia. Though the content of AA in liver was decreased by ethionine in rats, the content was significantly increased in guinea pigs. Ethionine may inhibit the utilization of AA in liver of guinea pigs. These results may support the thesis by Ginter (12) that AA is involved in cholesterol metabolism in guinea pigs.
It was reported that AAS has hypolipidemic effects in normal rats in a dose of 250mg/kg, in cholesterol-fed rats and rabbits in doses of 150 and 300mg/kg, and in cholesterol-fed guinea pigs at a dose of 300mg/kg, respectively (4) (5) (6) . In this experiments, AAS was effective at a dose of 300 mg/kg on fatty liver and/or hyperlipidemia induced by various treatments (Tables 2 and 5 ). Verlangieri et al. (7) observed hypolipidemic as well as antiatherosclerotic effects of AAS at a dose of 100mg/kg in cholesterol-fed rabbits. Machlin et al. (8) , however, reported that AAS at a lower dose (10mg/kg) did not produce hypolipidemic effects.
Ginter (12) reported that exogenous AA has no influence on cholesterolemia and atherosclerosis in animals synthesizing AA. In our experiments, AA had the effect or tendency of lowering the lipid levels in guinea pigs (Exps. 5-8), while AA had little effect in rats (Exps. 1-4). On the other hand, AAS was effective in both animals. The effects were, however, observed markedly in animals with impaired metabolism of AA; inhibited storage of AA (ethionine-and orotic acid-treated rats), impaired utilization of AA (ethionine-treated guinea pigs) and suppressed 2-SULFATE  AND  FATTY  LIVER  533 supply of AA (scorbutic guinea pigs). In general, AAS was more effective on hyperlipidemia and/or fatty liver induced endogenously by treatments such as ethionine , orotic acid or a scorbutigenic diet, while it was less effective on these symptoms induced exogenously by cholesterol supplement.
We reported previously that remarkable hypolipidemic and lipotropic effects were observed by long-term administration of AAS (10 to 20 weeks) on cholesterol-fed rabbits and guinea pigs (5 , 6) . In the present work, however, a slight effect was observed by short-term administration of AAS (4 weeks) on cholesterol fed guinea pigs (Table 5 ). Thus, if AAS is administered for a longer period in other experiments, more remarkable effects may be observed .
In many experiments, AAS was superior to AA in hypolipidemic effects but AA was more effective in increasing the AA content in the organ , suggesting that AAS exerts its hypolipidemic and lipotropic effects by the specific actions for AAS . Verlangieri and Mumma (16) reported an increased excretion of cholesterol sulfate into the feces of rats that received AAS by an intracardial injection . Hornig et al. (17) , however, reported that these effects were not observed in animals that were intravenously injected AAS and, 5 hr after the injection of AAS , [4-14C] cholesterol. Since most of the AAS intravenously injected was excreted within 5 hr into the urine (18) , the effects of AAS on the excretion of cholesterol sulfate should be studied further. We also observed that AAS produced increased fecal excretion of [4-14C] cholesterol injected intravenously in the guinea pigs (unpublished data). Thus, it is supposed that AAS may produce hypolipidemic effects through such direct actions of the compound as those on excretion of cholesterol, catabolism of cholesterol to bile acid and so on.
